• China’s ONLY senior clinical development event on quality drug development operation
  •  CO-LOCATED with 2 closely-related events: customize your own conference agenda!
  •   China’s FIRST EVER CRO Leadership Forum – Hear Exclusively From Local CRO Leaders!

IBC’s Clinical Trials China will be focused on best practices in clinical trial project management and operational excellence for China focusing on trial quality, medical communication and overall drug development in China.

Learn about how to smoothly integrate China operations into global clinical trials with focus on maintaining trial quality and timeline. If you oversee trial management, protocol design, clinical operations, medical affairs, CRO partnerships, clinical strategy, data management, site monitoring, on-site operations or clinical development for pharma company, biotech, medical device or CRO, this is an event you cannot miss!

Clinical Trials China will be a part of PharmaCon China 2016, the only senior industry gathering in China for accelerating global and regional drug development operations and quality clinical processes in China taking place from 28th to 31st March 2016.

Key Topics Addressed:

  • How Does China Fit into the Global Development Pathway for Big Pharma and Regional Biotech?
  • Regulatory Updates on Clinical Trials in Asian Countries
  • How to Make the Successful Transition from Registration Trials to Phase IV Studies?
  • Good Clinical Practice (GCP) and Trial Monitoring Operations
  • Best Practices in Clinical Operations and Project Management for China
  • Quality Trial Data Operations
  • Working With Partners and Stakeholders to Accelerate Trial Timelines in China

 

View full agenda »

 

IBC主办的中国临床试验国际峰会将侧重于中国临床试验项目管理和卓越操作的最佳实践,并以试验质量、医学交流及中国的整体药物研发为重点。

了解如何通过注重保持试验质量及时间安排,来将中国的业务与全球临床试验顺利整合。如果您负责试验管理、研究计划设计、临床操作、医疗事务、CRO合作伙伴关系、临床策略、数据管理、现场监测、现场操作或为制药公司、生物技术企业、医疗设备或CRO进行临床开发项目,那么您就不应错过这场盛会!

中国临床试验国际峰会 PharmaCon China 2016 的组成部分。PharmaCon China 2016 将于2016年3月28日至31日期间举行,是唯一一场在中国举行的资深业内人士聚集的专业会议,旨在加速全球及区域性的药物开发项目运作和中国高质量的临床流程。

探讨的重点议题:

  • 中国如何融入大型制药公司和区域生物技术企业的全球发展途径
  • 亚洲各国有关临床试验的法规更新
  • 如何从注册临床试验成功过渡到第四阶段研究?
  • 药物临床试验质量管理规范(GCP)与试验监测运作
  • 中国在临床运作和项目管理方面的最佳实践
  • 质量试验数据操作
  • 与合作伙伴及利益相关者携手合作,以加速中国的试验时间安排

查看完整议程 »

 

A Stellar Line Up of Speakers Include:

Li Chen
CEO
Hua Medicine, China
Xian Ping Lu
CEO
Shenzhen Chipscreen Biosciences, China
Ye Hua
Senior Vice President, Clinical Development and Regulatory Affairs
Hutchison Medipharma, China
Weikang Tao
CEO, R&D Centre
Shanghai Hengrui Medicine, China
Ming-Qiang Zhang
Corporate Vice-President, Research & Development
Amgen, China
Ming-Chu Hsu
Chairman of the Board & CEO
TaiGen Biotechnology, Taiwan
Joan Shen
Vice President, Development Head China R&D and Scientific Affairs
Janssen Pharmaceuticals, China
Friedhelm Blobel
CEO
SciClone Pharmaceuticals, USA & China
Dan Paulson
Vice President, Global Clinical Development, Group Head, Cardiometabolism Risk Management and Antiinfectives
Bayer HealthCare Pharmaceuticals, China
Christina Bodurow
Senior Director, External Sourcing, Development Center of Excellence
Eli Lilly and Co, USA

View all speakers »

 

 

Produced byBronze SponsorSession Spotlight Sponsor
Exhibitors  
  
Supporting Associations 
Media Partners  
IBC

  
International Marketing Partner